1. Biochemically Recurrent Prostate Cancer: Optimizing Detection and Management

2. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Prostate Cancer Incidence and Significance of BCR

4. Defining BCR After RP

5. Defining BCR After RT

6. Clinical Implications of a Rising PSA

7. Mortality After BCR Following RP Retrospective Cohort Study

8. Current Management of BCR Prostate Cancer

9. Diagnostic Evaluation of Patients With BCR

10. NaF-PET/CT An Alternative to Conventional Scanning

11. PET in BCR Prostate Cancer

12. PET Radiopharmaceuticals Approved or Under Evaluation in Prostate Cancer

13. Recommendations for PET/CT in Men With BCR

14. Choline: Overview

15. Use of 11C-Choline-PET/CT in Patients With BCR

16. Example of 11C-Choline-PET/CT in a Patient With BCR

17. 11C-Choline-PET/CT Sensitivity by PSA Level

18. 18F-Fluciclovine (FACBC): Overview

19. 18F-Fluciclovine-PET/CT in BCR Prostate Cancer BED-001 Study

20. Prospective Study of 18F-Fluciclovine-PET/CT vs 11C-Choline-PET/CT in BCR Prostate Cancer

21. Example of 18F-Fluciclovine-PET/CT

22. 18F-Fluciclovine-PET/CT Scan Showing Metastatic Prostate Cancer 2 Months Later

23. PSMA: An Investigational PET Imaging Target

24. Example of 18F-DCFPyL PET/CT Imaging in a Patient With BCR Prostate Cancer

25. Example of 68Ga PSMA PET/CT Imaging

26. Targeting Oligometastatic Prostate Cancer

28. Conclusions

29. Abbreviations

30. Abbreviations (cont)